Case Report: Pulmonary alveolar adenoma: a case series from a single institution and literature review - Top-Institutions - MDSpire

Case Report: Pulmonary alveolar adenoma: a case series from a single institution and literature review

  • By

  • Martina Maione

  • Jose Coelho Lima

  • Giuseppe Maggioni

  • Chiara Giraudo

  • Federica Pezzuto

  • Fiorella Calabrese

  • June 29, 2026

  • 0 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    our institution
    our institution

    Unknown, Unknown

    Key Differentiators

    • Pulmonology

  • #2

    First Affiliated Hospital of Kunming Medical University
    First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan

    Key Differentiators

    • Pathology

  • #3

    San Luigi Gonzaga Hospital
    San Luigi Gonzaga Hospital

    Orbassano, Piedmont

    Key Differentiators

    • Radiology

  • #4

    AOU Città della Salute e della Scienza di Torino
    AOU Città della Salute e della Scienza di Torino

    Turin, Piedmont

    Key Differentiators

    • Research

  • #5

    American-Australian-Asian Adrenal Alliance
    American-Australian-Asian Adrenal Alliance

    Unknown, Unknown

    Key Differentiators

    • Endocrinology

Original Source(s)

Case Report: Pulmonary alveolar adenoma: a case series from a single institution and literature review

  • by Martina Maione, Jose Coelho Lima, Giuseppe Maggioni, Chiara Giraudo, Federica Pezzuto, Fiorella Calabrese

  • June 29, 2026

Related Content

Cracking H5N1's Cattle Code

Research helps explain why avian influenza concentrates in the bovine mammary gland

  • June 29, 2026

  • 2 min
HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.